{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-006430","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.899493+00:00","generated_at":"2026-05-26T10:24:51.795591+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cumberland gets NMPA approval in China for Vibativ; exclusive deal with SciClone","bullets":["Vibativ (telavancin) approved by China's NMPA for hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections.","SciClone granted exclusive rights to register, promote, and distribute Vibativ in China.","Companies plan to launch Vibativ in China later in 2025.","Vibativ is a once-daily IV antibiotic designed to treat multidrug-resistant Gram-positive bacteria."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-006430","json":"https://secwatch.observer/filing/0001628280-25-006430.json","markdown":"https://secwatch.observer/filing/0001628280-25-006430.md","text":"https://secwatch.observer/filing/0001628280-25-006430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025006430/0001628280-25-006430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828025006430/cpix-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T10:24:51.795591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}